Satellos Bioscience Inc Stock Price, News & Analysis

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing treatments for degenerative muscle diseases, has announced its participation in two major investor conferences in April 2025.

The company will deliver a presentation at the Oppenheimer Innovation on the Island conference in San Juan, Puerto Rico on April 10, 2025, at 10:08 a.m. AST. Additionally, Satellos will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 16, 2025.

Satellos Bioscience (MSCLF) has reported its 2024 financial results and key milestones. The company completed enrollment and dosing in a Phase 1a clinical trial with 72 healthy volunteers for SAT-3247, demonstrating safety and intended pharmacokinetic profile. A Phase 1b trial has been initiated in up to 10 adults with Duchenne muscular dystrophy (DMD), with data expected in Q2 2025.

The company closed a US$40 million equity offering in December 2024, resulting in a strong cash position of $69.9 million as of December 31, 2024. The net loss for 2024 was $28.1 million ($0.25 per share), compared to $15.9 million in 2023. R&D expenses increased to $19.6 million from $8.8 million, while G&A expenses rose to $8.2 million from $6.6 million. Management projects current cash runway through 2026.

Satellos Bioscience (OTCQB: MSCLF) has presented initial Phase 1 data for SAT-3247, their oral therapy candidate for Duchenne Muscular Dystrophy (DMD), at the 2025 MDA Clinical & Scientific Conference.

The Phase 1a trial involved 72 healthy volunteers across five single ascending dose cohorts (up to 400 mg) and four multiple ascending dose cohorts (up to 240 mg/day for 7 days). Key findings show that SAT-3247 was safe and well-tolerated, with no moderate or greater drug-related adverse events reported. The pharmacokinetic profile demonstrated consistency with preclinical studies, maintaining plasma concentrations at levels expected to benefit muscle regeneration and strength.

The drug is designed to address progressive muscle loss in DMD patients by targeting muscle regeneration. A Phase 1b trial in adults with DMD is currently ongoing, with full Phase 1a and 1b data expected in Q2 2025.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has announced an upcoming oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, scheduled for March 16-19. The presentation will showcase the company's first-ever Phase 1 safety and pharmacokinetic data for their drug candidate SAT-3247.

The presentation, titled 'First-in-human Phase 1 study of orally administered SAT-3247 in healthy volunteers and adult participants with Duchenne Muscular Dystrophy (DMD),' will be delivered by Chief Scientific Officer Phil Lambert on Wednesday, March 19, 2025, at 8:00 AM CT in the Coronado ABCD room at the Hilton Anatole, Dallas. The presentation materials will be made available on the company's investor relations website following the session.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has completed enrollment of all four multiple-ascending dose (MAD) cohorts in its Phase 1 clinical trial of SAT-3247 in healthy volunteers. The company remains on track to report Phase 1a data from both Single-Ascending Dose (SAD) and MAD cohorts in Q1 2025.

The Phase 1b portion of the trial, targeting Duchenne Muscular Dystrophy (DMD) patients, is currently underway with plans to enroll up to 10 adult volunteers with genetically confirmed DMD during Q1 2025. The company also expects to submit its Phase 2 IND filing by the end of Q1 2025.

SAT-3247 is being developed as an oral, once-daily therapy aimed at restoring muscle regeneration and repair in all DMD patients, with potential use as either a standalone or add-on treatment.

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF), a biotech company focused on developing small molecule therapeutics for muscle diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual conference will take place on February 11-12, 2025.

Co-founder and CEO Frank Gleeson will deliver a corporate presentation on February 11 at 1:20 p.m. ET and will join other management team members in one-on-one meetings throughout the conference. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the presentation.

Bloom Burton & Co has announced changes in its holdings of Satellos Bioscience Inc. The firm acquired 1,692,250 common shares at $0.90 per share, totaling $1,523,025, through a public offering dated December 17, 2024. Despite this acquisition, Bloom Burton's beneficial holdings decreased by approximately 3.7% on a partially diluted basis.

Following the transaction, Bloom Burton, its affiliates, and Brian Bloom now own 10,400,818 shares and 7,528,732 derivative securities, representing approximately 6.3% ownership on a non-diluted basis and 10.3% on a partially diluted basis. Previously, they held 8,708,568 shares and 7,528,732 derivative securities, representing 7.6% non-diluted and 13.3% partially diluted ownership.

Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF) has successfully closed a US$40 million equity offering, issuing 63,285,000 equity securities at $0.90 per common share. The offering consisted of 51,420,000 common shares and 11,865,000 pre-funded common share purchase warrants.

The offering was led by Bloom Burton Securities Inc., alongside Canaccord Genuity Corp., Haywood Securities Inc., and Leede Financial Inc. The net proceeds will fund the company's Phase 2 clinical development of SAT-3247, working capital needs, and general corporate purposes.

Notable insider participation included board member Franklin Berger (320,000 shares), CEO Frank Gleeson (160,000 shares), and Bloom Burton & Co Inc. (1,692,250 shares).

Satellos Bioscience (MSCLF) has announced the pricing of its overnight marketed public offering, aiming to raise up to US$40 million. The offering includes up to 63,285,000 securities at $0.90 per security, consisting of common shares or pre-funded warrants. The warrants can be exercised at a nominal price with no expiration date.

The offering is being conducted through a syndicate led by Bloom Burton Securities, including Canaccord Genuity, Haywood Securities, and Leede Financial. Expected to close around December 20, 2024, the proceeds will fund Phase 2 clinical development of SAT-3247, working capital needs, and general corporate purposes.